key: cord-1052835-b2ttlkbp
authors: ALIDJINOU, Enagnon Kazali; GAILLOT, Olivier; GUIGON, Aurélie; TINEZ, Claire; LAZREK, Mouna; BOCKET, Laurence; ENGELMANN, Ilka; HOBER, Didier
title: SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies
date: 2021-10-02
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115565
sha: 144156a9af8c7910a9451d643fc3e351667d4469
doc_id: 1052835
cord_uid: b2ttlkbp

SARS-CoV-2 infections after COVID-19 vaccination are not unexpected, but those occurring more than 14 days after second vaccine dose need to be investigated. We describe a well-characterized infection which occurred almost 2 months after full vaccination, and provide the evidence of a link with a lack of anti-SARS-CoV-2 neutralizing antibodies.

Detailed studies investigating immune response in vaccine breakthrough cases are needed.

Our observation is in agreement with a recent case-control study in Israel which found low 119 antibody levels in vaccine breakthrough cases as compared to controls (Bergwerk et al., 2021) .

Antibody levels obtained with routine ELISA quantitative assays should be interpreted with 121 caution, because they might not reflect serum neutralizing activity, as observed in this report.

The correlation between these tests and seroneutralization assays need to be studied in sera from 123 both patients with confirmed SARS-CoV-2 past infection, and vaccinated people.

In conclusion, the investigation of COVID-19 vaccine breakthrough cases should also consider 125 the evaluation of the host response, including testing for serum neutralizing activity. 

Covid-19 Breakthrough 140 Infections in Vaccinated Health Care Workers

Novel SARS-CoV-2 variants: 143 the pandemics within the pandemic

1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of 147

COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Vaccine in a Nationwide Mass Vaccination Setting

Infection after Vaccination in Health Care Workers in California

Sensitivity of 156 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural

Interim 163 Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in 164

Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders